colistin and HIV-Infections

colistin has been researched along with HIV-Infections* in 3 studies

Other Studies

3 other study(ies) available for colistin and HIV-Infections

ArticleYear
Intestinal colonisation with extended-spectrum cephalosporin- and colistin-resistant Enterobacteriaceae in HIV-positive individuals in Switzerland: molecular features and risk factors.
    International journal of antimicrobial agents, 2017, Volume: 49, Issue:4

    Topics: Anti-Bacterial Agents; beta-Lactamases; CD4 Lymphocyte Count; Cephalosporins; Cohort Studies; Colistin; Drug Resistance, Multiple, Bacterial; Dysbiosis; Enterobacteriaceae; Enterobacteriaceae Infections; Escherichia coli Proteins; Feces; HIV Infections; Humans; Intestines; Microbial Sensitivity Tests; Microbiota; Plasmids; Risk Factors; Switzerland

2017
A retrospective study on the effects of colistin therapy in children with multidrug-resistant Gram-negative bacterial pathogens: impact of HIV status on outcome.
    Archives of disease in childhood, 2014, Volume: 99, Issue:3

    Nosocomially acquired multidrug-resistant (MDR) Gram-negative bacteria are important contributors to paediatric intensive care unit (PICU) mortality and morbidity, with limited treatment options.. To investigate the outcomes of all children treated with colistin for infection with MDR Gram-negative bacteria while admitted to PICU.. Retrospective observational study of 19 months. Primary endpoints were all-cause intensive care unit mortality and safety. Secondary endpoints evaluated clinical and microbiological outcomes. Cases were stratified according to HIV status.. Twenty-seven children received 30 colistin courses during the study period. Eight patients (29.6%) were HIV infected, six (22.2%) were HIV uninfected but exposed, and 11 (40.7%) were HIV uninfected and unexposed. Common MDR Gram-negative bacteria cultured were: Acinetobacter species (n=22, 81.5%), Pseudomonas aeruginosa (n=11, 40.7%) and Klebsiella pneumoniae (n=7, 25.9%). Mortality was 37%, with no significant difference between HIV strata. No adverse drug reactions were noted. A composite clinical improvement was noted in 16 courses (53.3%) of colistin. Only 30% of colistin courses used in HIV-infected children resulted in an improved clinical assessment as compared with 83.3% of courses in HIV-uninfected/unexposed children (p=0.04). In HIV-infected children, five of 10 (50%) courses of colistin showed bacteriological clearance compared to the HIV uninfected/unexposed group where all cases showed bacterial eradication (p=0.02).. HIV-infected children had poorer clinical and bacteriological responses to colistin treatment than HIV uninfected/unexposed. These results require confirmation with prospective studies to determine whether findings are due to poor microbial response, immunodeficiency or repeated reinfections.

    Topics: Anti-Bacterial Agents; Child Mortality; Child, Preschool; Colistin; Drug Resistance, Multiple, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; HIV Infections; Humans; Infant; Intensive Care Units, Pediatric; Male; Retrospective Studies; South Africa; Treatment Outcome

2014
Prolonged efficiency of secondary prophylaxis with colistin aerosols for respiratory infection due to Pseudomonas aeruginosa in patients infected with human immunodeficiency virus.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1996, Volume: 23, Issue:3

    Topics: Adult; Aerosols; Anti-Bacterial Agents; Colistin; HIV Infections; HIV-1; Humans; Male; Pseudomonas Infections; Respiratory Tract Infections

1996